In recent studies, our lab has demonstrated that TRAIL-coated leukocytes via the administration of liposomal TRAIL can be effective in eradicating circulating tumor cells (CTCs) in the blood of metastatic cancer patients (Ortiz-Otero et al., 2020). Here, TNFSF10 is linked to metastatic malignant neoplasm.